These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 7913520)

  • 21. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges.
    Katzenschlager R; Hughes A; Evans A; Manson AJ; Hoffman M; Swinn L; Watt H; Bhatia K; Quinn N; Lees AJ
    Mov Disord; 2005 Feb; 20(2):151-7. PubMed ID: 15390035
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Treatment of motor fluctuations in Parkinson's disease with subcutaneous injections of apomorphine].
    Merello M; Leiguarda R
    Medicina (B Aires); 1995; 55(1):5-10. PubMed ID: 7565037
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Accuracy of acute levodopa challenge for clinical prediction of sustained long-term levodopa response as a major criterion for idiopathic Parkinson's disease diagnosis.
    Merello M; Nouzeilles MI; Arce GP; Leiguarda R
    Mov Disord; 2002 Jul; 17(4):795-8. PubMed ID: 12210878
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Open-label study assessment of safety and adverse effects of subcutaneous apomorphine injections in treating "off" episodes in advanced Parkinson disease.
    LeWitt PA; Ondo WG; Van Lunen B; Bottini PB
    Clin Neuropharmacol; 2009; 32(2):89-93. PubMed ID: 18978491
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Apomorphine-induced penile erections in Parkinson's disease.
    O'Sullivan JD; Hughes AJ
    Mov Disord; 1998 May; 13(3):536-9. PubMed ID: 9613749
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Shifting to subcutaneous infusion of apomorphine in advanced Parkinson's disease patients on an out-patient basis: experience and recommendations].
    Castaño B; Mateo D; Giménez-Roldán S
    Neurologia; 2007 Apr; 22(3):133-7. PubMed ID: 17364250
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Apomorphine for treatment of "off-periods" in Parkinson's disease].
    Zoldan J; Merims D; Kuritzky A; Ziv I; Melamed E
    Harefuah; 1999 Nov; 137(10):444-6, 512, 511. PubMed ID: 10959339
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recent advances in the clinical pharmacology of Parkinson's disease.
    Montastruc JL
    Therapie; 1991; 46(4):293-303. PubMed ID: 1683024
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Subcutaneous administration of apomorphine in motor fluctuations in Parkinson's disease].
    Pollak P; Champay AS; Gaio JM; Hommel M; Benabid AL; Perret J
    Rev Neurol (Paris); 1990; 146(2):116-22. PubMed ID: 2320817
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of apomorphine and levodopa infusions in four patients with Parkinson's disease with symptom fluctuations.
    Nyholm D; Constantinescu R; Holmberg B; Dizdar N; Askmark H
    Acta Neurol Scand; 2009 May; 119(5):345-8. PubMed ID: 18822087
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics and clinical efficacy of rectal apomorphine in patients with Parkinson's disease: a study of five different suppositories.
    van Laar T; Jansen EN; Neef C; Danhof M; Roos RA
    Mov Disord; 1995 Jul; 10(4):433-9. PubMed ID: 7565822
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years.
    Hughes AJ; Bishop S; Kleedorfer B; Turjanski N; Fernandez W; Lees AJ; Stern GM
    Mov Disord; 1993 Apr; 8(2):165-70. PubMed ID: 8474483
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of central dopaminergic stimulation by apomorphine on swallowing disorders in Parkinson's disease.
    Tison F; Wiart L; Guatterie M; Fouillet N; Lozano V; Henry P; Barat M
    Mov Disord; 1996 Nov; 11(6):729-32. PubMed ID: 8914103
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Continuous subcutaneous apomorphine infusions for fluctuating Parkinson's disease. Long-term follow-up in 18 patients.
    Poewe W; Kleedorfer B; Wagner M; Bösch S; Schelosky L
    Adv Neurol; 1993; 60():656-9. PubMed ID: 8420206
    [No Abstract]   [Full Text] [Related]  

  • 35. [Apomorphine in the treatment of Parkinson disease].
    Christensen PB; Dupont E; Jensen NB
    Ugeskr Laeger; 1991 Sep; 153(38):2631-4. PubMed ID: 1949272
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Repeated rating improves value of diagnostic dopaminergic challenge tests in Parkinson's disease.
    Müller T; Benz S; Börnke C; Russ H; Przuntek H
    J Neural Transm (Vienna); 2003 Jun; 110(6):603-9. PubMed ID: 12768356
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Sublingual administration of apomorphine in the treatment of motor fluctuations in Parkinson disease].
    Durif F; Deffond D; Eschalier A; Tournilhac M
    Rev Neurol (Paris); 1992; 148(10):610-4. PubMed ID: 1295055
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Apomorphine test for dopaminergic responsiveness.
    Lancet; 1989 Jun; 1(8649):1262-3. PubMed ID: 2566801
    [No Abstract]   [Full Text] [Related]  

  • 39. Apomorphine test for dopaminergic responsiveness in patients with previously untreated Parkinson's disease.
    Gasser T; Schwarz J; Arnold G; Trenkwalder C; Oertel WH
    Arch Neurol; 1992 Nov; 49(11):1131-4. PubMed ID: 1444878
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Worsened motor test performance following acute apomorphine injection in previously untreated patients with Parkinson's disease.
    Müller T; Benz S; Börnke Ch; Muhlack S; Woitalla D; Przuntek H
    J Neural Transm Suppl; 2004; (68):79-87. PubMed ID: 15354392
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.